Revenue rose to $75.3M, but net loss widened to $194.3M year-over-year. REDEMPLO doubled prescription volume and gained new approvals, while SHASTA-3/4 studies showed strong efficacy for plozasiran. Pipeline and global expansion advanced, with significant licensing and regulatory milestones.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.